Genetic, Epigenetic and Transcriptome Alterations in Liposarcoma for Target Therapy Selection

Ekaterina A. Lesovaya,Timur I. Fetisov,Beniamin Yu. Bokhyan,Varvara P. Maksimova,Evgeny P. Kulikov,Gennady A. Belitsky,Kirill I. Kirsanov,Marianna G. Yakubovskaya

DOI: https://doi.org/10.3390/cancers16020271

2024-01-09

Cancers

Abstract:Liposarcoma (LPS) is one of the most common adult soft-tissue sarcomas (STS), characterized by a high diversity of histopathological features as well as to a lesser extent by a spectrum of molecular abnormalities. Current targeted therapies for STS do not include a wide range of drugs and surgical resection is the mainstay of treatment for localized disease in all subtypes, while many LPS patients initially present with or ultimately progress to advanced disease that is either unresectable, metastatic or both. The understanding of the molecular characteristics of liposarcoma subtypes is becoming an important option for the detection of new potential targets and development novel, biology-driven therapies for this disease. Innovative therapies have been introduced and they are currently part of preclinical and clinical studies. In this review, we provide an analysis of the molecular genetics of liposarcoma followed by a discussion of the specific epigenetic changes in these malignancies. Then, we summarize the peculiarities of the key signaling cascades involved in the pathogenesis of the disease and possible novel therapeutic approaches based on a better understanding of subtype-specific disease biology. Although heterogeneity in liposarcoma genetics and phenotype as well as the associated development of resistance to therapy make difficult the introduction of novel therapeutic targets into the clinic, recently a number of targeted therapy drugs were proposed for LPS treatment. The most promising results were shown for CDK4/6 and MDM2 inhibitors as well as for the multi-kinase inhibitors anlotinib and sunitinib.

oncology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to understand the genetic, epigenetic and transcriptomic alterations in different subtypes of liposarcoma (LPS) in order to select targeted treatment options. Specifically, the paper explores the following points:

1. **Genetic Abnormalities**:
- The paper details the common genetic abnormalities in different subtypes of liposarcoma (such as well - differentiated liposarcoma WDLPS, dedifferentiated liposarcoma DDLPS, myxoid/round cell liposarcoma MLPS, pleomorphic liposarcoma PLPS and myxoid pleomorphic liposarcoma MPLPS).
- For example, the amplification in the 12q13 - 15 region commonly seen in WDLPS and DDLPS, and the unique FUS - CHOP gene fusion in MLPS.

2. **Epigenetic Alterations**:
- The paper discusses the epigenetic alterations in liposarcoma, including changes in DNA methylation, histone modification and miRNA expression.
- For example, the specific methylation profile in DDLPS is related to clinical prognosis, and the specific methylation profile in the 12q13 - q14 region in MLPS is also described.

3. **Transcriptomic Changes**:
- The paper analyzes the transcriptomic changes in different subtypes of liposarcoma, which may affect tumorigenesis and development.
- For example, the over - expression or under - expression of certain genes in WDLPS and DDLPS, and the expression changes of specific miRNAs in MLPS.

4. **Selection of Targeted Therapy**:
- Based on the above - mentioned genetic, epigenetic and transcriptomic alterations, the paper explores possible targeted treatment strategies.
- For example, the application of CDK4/6 inhibitors and MDM2 inhibitors in WDLPS and DDLPS, and the potential of multi - kinase inhibitors such as anlotinib and sunitinib in the treatment of liposarcoma.

Through these studies, the paper aims to provide a scientific basis for precision medicine in liposarcoma, especially in terms of selecting appropriate targeted treatment options.